申请人:Sznaidman Marcos
公开号:US20060036092A1
公开(公告)日:2006-02-16
This application provides a process for preparing enantiomerically pure β-D-dioxolane nucleosides. In particular, a new synthesis of (−)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure β-D- or β-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected β-D- or P-L-1,3-dioxolane nucleoside.
该应用程序提供了一种制备对映纯β-D-二氧杂环核苷的方法。具体来说,描述了一种适用于大规模开发的新合成方法,用于制备(−)-DAPD。在一种实施方式中,该发明提供了一种制备基本纯β-D-或β-L-1,3-二氧杂环核苷的方法,包括a) 制备或获取酯化的2,2-二烷氧基乙醇;b) 将酯化的2,2-二烷氧基乙醇与甘醇酸环化以获得1,3-二氧杂环内酯;c) 分解1,3-二氧杂环内酯以获得基本纯的D-或L-内酯;d) 选择性还原和激活D-或L-手性内酯以获得基本纯的D-或L-1,3-二氧杂环;e) 将D-或L-1,3-二氧杂环与激活和/或保护的嘌呤或嘧啶碱基偶联;f) 可选地纯化核苷以获得基本纯的保护的β-D-或P-L-1,3-二氧杂环核苷。